Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)
- Combination trial accrual completed in first cohort of patients- Commercial grade AGEN1884 and AGEN2034 to be available by mid-year- Non-exclusive access to partners for clinical and commercial supp...
Page (1) of 1 - 01/22/18||
(January 22, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved